MARKET

CRIS

CRIS

Curis
NASDAQ
2.030
-0.090
-4.25%
Opening 15:26 05/14 EDT
OPEN
2.160
PREV CLOSE
2.120
HIGH
2.270
LOW
1.900
VOLUME
151.55K
TURNOVER
--
52 WEEK HIGH
16.80
52 WEEK LOW
1.020
MARKET CAP
21.24M
P/E (TTM)
-0.3259
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (0505-0509)?
Weekly Report · 2d ago
Curis’s Strategic Clinical Advancements and Positive Regulatory Feedback Underpin Buy Rating
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Ardent Health Partners, Inc. (ARDT) and Agilon Health (AGL)
TipRanks · 05/07 11:41
Curis files to sell 10.5M shares of common stock for holders
TipRanks · 05/07 10:21
Curis Inc. Reports Q1 2025 Progress and Financials
TipRanks · 05/07 04:42
Curis Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 05/07 02:14
Curis Inc. Earnings Call: Clinical Advances Amid Cash Concerns
TipRanks · 05/07 01:21
CURIS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/06 22:16
More
About CRIS
More
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Recently
Symbol
Price
%Change

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.